Finnish study highlights the need for mRNA COVID vaccine booster shots
Vaccines | Free Full-Text | Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?
What We Know So Far About Waning Vaccine Effectiveness - The New York Times
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar | Nature Medicine
Boosters provide high level of protection against death with Omicron - GOV.UK
Omicron infection is a poor booster of COVID-19 immunity | Imperial News | Imperial College London
COVID-19 Vaccines and Booster Shots: Which Combination is Most Effective? - Homage Malaysia
BNT162b2 Vaccine Booster and Mortality Due to Covid-19 | NEJM
Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine
Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study - The Lancet Regional Health – Americas
Vaccines and Boosters: Our Best Defense Against COVID-19
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study - The Lancet
What We Know About Getting a Second Booster Shot of COVID-19 Vaccines | The Scientist Magazine®
Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022 | MMWR
Booster and Additional Primary Dose COVID-19 Vaccinations Among Adults Aged ≥65 Years — United States, August 13, 2021–November 19, 2021 | MMWR
A Bivalent Omicron-Containing Booster Vaccine against Covid-19 | NEJM
What is a booster shot and why do I need it? | OSF HealthCare
Covid booster doses will be offered to over-40s - BBC News
What We Know About Getting a Second Booster Shot of COVID-19 Vaccines | The Scientist Magazine®
Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design - The Lancet Infectious Diseases
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials - The Lancet
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR
